- Teva Pharmaceutical Industries (NYSE:TEVA -0.7%) acquires Labrys Biologics for as much as $825M ($200M upfront and up to $625M in milestone payments). Labrys's lead product is LBR-101, an anti-CGRP mAb for the prevention of chronic and high frequency episodic migraines. Peak sales of the product could hit $2B - 3B. It is currently in a Phase 2b clinical trial.
Teva buys migraine maker
Recommended For You
About TEVA Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
TEVA | - | - |
Teva Pharmaceutical Industries Limited |